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Summary The proportion of patients with antituberculosis drug-induced hepatotoxicity (ATDH) was unexpectedly
low during a trial on cotrimoxazole prophylaxis in Malawian HIV-positive pulmonary tuberculosis
patients. About 2% of the patients developed grade 2 or 3 hepatotoxicity during tuberculosis (TB)
treatment, according to WHO deﬁnitions. Data on ATDH in sub-Saharan Africa are limited. Although
the numbers are not very strong, our trial and other papers suggest that ATDH is uncommon in this
region. These ﬁndings are encouraging in that hepatotoxicity may cause less problem than expected,
especially in the light of combined HIV/TB treatment, where drug toxicity is a major cause of treatment
interruption.
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Treatment adherence is crucial for curing patients with
active tuberculosis (TB). Adverse effects of TB treatment
signiﬁcantly contribute to non-adherence, which has its
consequences for TB control. Antituberculosis drug-
induced hepatotoxicity (ATDH) is a serious adverse effect,
which causes substantial morbidity and mortality, com-
plicating TB treatment. The incidence of ATDH has been
variably reported as between 2% and 11% (Dossing et al.
1996; Schaberg et al. 1996; Yee et al. 2003; Fernandez-
Villar et al. 2004). This rate depends on the investigators’
deﬁnition of hepatotoxicity as well as the population
studied. Most studies on ATDH are performed in Europe,
Southeast Asia and northern America. Data on ATDH in
sub-Saharan Africa are limited. This is probably due to the
fact that transaminases are not measured routinely and
hepatotoxicity is often diagnosed clinically by the occur-
rence of jaundice.
We report the proportion of antituberculosis drug-
induced hepatotoxicity cases observed in a randomised
clinical trial on cotrimoxazole (CTX) prophylaxis in 579
Malawian HIV-positive adult tuberculosis patients. They
were treated for smear-positive pulmonary TB with an
8-monthregimenof1SHRZ/1S3H3R3Z3/6HE(seeBox 1for
explanation) plus daily CTX at a dose of 480 or 960 mg
(Boereeet al.2005).Nonereceivedantiretroviraltreatment.
They were followed-up every 4 weeks until the end of TB
treatment and aminotransferase levels [aspartate amino-
transferase (ASAT) and alanine aminotranferase (ALAT)]
were measured at enrolment and at months 2, 5 and 8.
During TB treatment, ﬁve patients (1.3%) developed
grade 2 hepatotoxicity and three patients (0.9%) developed
grade 3 hepatotoxicity according to WHO deﬁnitions
(WHO 1992). No grade 4 hepatotoxicity was observed in
this cohort. Table 1 shows the number of patients with
hepatotoxicity at different time points during the study.
Patients with grade 1 toxicity were still at risk for toxicity
on subsequent measurements.
In this study, ALAT >50 u/l at inclusion and male
gender were associated independently with ATDH
(Table 2). In multivariate analysis, both ALAT >50 u/l at
inclusion and male gender tend to be associated with
ATDH [adjusted hazard ratios 2.18 (95%CI 0.93–5.07)
and 1.58 (95%CI 0.99–2.53) respectively], although at
borderline statistical signiﬁcance. Whether hepatotoxicity
was related to alcohol use, HIV infection or concomitant
use of other hepatotoxic drugs cannot be concluded from
our data. Due to the small numbers, grade 1 toxicity was
included in these analyses.
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44 (7.6%) were lost to follow-up and the trial was stopped
in 13 patients (2.2%) upon their request (Figure 1). Most
deaths were because of TB (n ¼ 22), diarrhoea (n ¼ 19)
and meningitis (n ¼ 11); the other causes are summarised
in the original paper of Boeree et al. (2005).
Patients who died or were withdrawn from the trial were
more likely to have an ALAT level of >50 u/l at inclusion
(9.3%) than patients who remained followed-up until the
end of treatment [2.9% (P ¼ 0.02)]. Therefore, these
patients were possibly more at risk for ATDH, which could
give an underestimation of ATDH in our trial (Fernandez-
Villar et al. 2004).
The inclusion criteria for the trial are summarised in the
original paper. The most relevant inclusion criterion in our
study is HIV infection, as this is a risk factor for ATDH
(Yee et al. 2003). Four patients were excluded because of
‘jaundice or liver problems’. Regarding the low number,
we did not expect this to affect the generalisability of our
ﬁndings. A total of 80 patients were ineligible according to
the exclusion criteria, mostly because of having received
TB drugs for more than 8 days. We assume that these
criteria were not related to (risk factors for) ATDH.
The low proportion of ATDH in our trial is consistent
with the previous studies in sub-Saharan Africa. In a study
in former Zaire, TB drugs (2HRZE/4HR) were well
tolerated among 446 TB patients. No hepatitis was
reported, but increased transaminase-levels were occa-
sionally seen (Perriens et al. 1995). In a Ugandan study,
only two of 265 HIV-infected subjects (1%) developed
hepatotoxicity during treatment of pulmonary TB
(2HRZE/6HR) (Johnson et al. 2000). The same group
reported that hepatitis and transaminase elevations did
occur during preventive TB treatment in HIV-positive
patients and that 0.8% had transaminase levels >135 u/l
(Whalen et al. 1997).
These reports suggest that the incidence of ATDH in
adults is low in sub-Saharan Africa. This is unexpected,
because risk factors such as HIV or hepatitis B and C
infection are highly prevalent in this region. There are
several possible reasons for this apparently low incidence
of ATDH. First, the available studies were not designed to
detect ATDH. Cases of mild or transient hepatotoxicity
Box 1 Tuberculosis treatment regimens
H, isoniazid; R, rifampin; Z, pyrazinamide; E, ethambutol;
S, streptomycin.
The regular-size number refers to the number of months this
regimen is used, the subscript number refers to how many
times per week a drug is taken. For example: 1SHRZ/
1S3H3R3Z3/6HE ¼ one month of daily streptomycin, iso-
niazid, rifampin and pyrazinamide, followed by 1 month of
the same four drugs three times a week, followed by 6 months
of daily isoniazid and ethambutol.
Table 1 Patients with hepatotoxicity during tuberculosis treat-
ment
Month 2 Month 5 Month 8
No. of patients still
followed
526 478 437
No. of patients
measured
446 (84.8%) 376 (78.7%) 333 (76.2%)
No hepatotoxicity
(ALAT<50 U/l)
410 336 302
Grade 1* 35 (7.8%) 35 (9.3%) 29 (8.7%)
Grade 2 1 (0.2%) 4 (1.1%) –
Grade 3 – 1 (0.3%) 2 (0.6%)
Grade 4 – – –
ALAT ¼ alanine aminotransferase.
*WHO deﬁnition of drug-induced hepatotoxicity.
Grade 1 (mild): <2.5 · the upper limit of normal (ULN) (ALAT
51–125 U/l).
Grade 2 (mild): 2.6–5 · the ULN (ALAT 126–250 U/l).
Grade 3 (moderate): 5–10 · the ULN (ALAT 251–500 U/l).
Grade 4 (severe): >10 · the ULN (ALAT >500 U/l).
Table 2 Baseline characteristics according to hepatotoxicity sta-
tus and univariate analysis among 464 patients with liver function
information at 2, 5 and/or 8 months (Cox proportional hazards
model)
Hepatotoxicity*
%, (n/N)
Hazard ratio
(CI 95%)
Sex
Female 15.1% (36/239) Ref*
Male 23.6% (53/225) 1.71 (1.12–2.62)
CTX prophylaxis
CTX 480 mg 19.1% (42/220) Ref
CTX 960 mg 19.3% (47/244) 1.02 (0.67–1.55)
Age
15–24 17.2% (17/99) Ref
25–34 18.2% (39/214) 1.08 (0.61–1.91)
35–44 22.1% (25/113) 1.32 (0.71–2.44)
>45 21.6% (8/37) 1.28 (0.55–2.97)
CD4-count
0–99 20.7% (25/121) Ref
100–199 17.3% (22/127) 0.78 (0.44–1.39)
200–349 19.6% (20/102) 0.93 (0.52–1.68)
>350 19.6% (18/92) 0.91 (0.50–1.68)
Hepatotoxicity at inclusion*
No 18.4% (82/446) Ref
Yes 35.3% (6/17) 2.23 (0.97–5.10)
ALAT, alanine aminotransferase; CTX, cotrimoxazole; CI 95%,
95% conﬁdence interval; Ref, reference value.
*Hepatotoxicity is deﬁned as grade 1 or higher.
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monitored only four times during TB treatment. Conse-
quently, the incidence of mild ATDH may be under-
estimated. However, as serious hepatotoxicity would have
most probably been detected at the monthly follow-up
visits, we do not consider this possible underestimation
clinically relevant. Second, patients who were withdrawn
from the trial were probably at higher risk of ATDH than
patients who remained in the study until the end of
treatment. This could result in an underestimation of
hepatotoxicity in our trial. Third, there is some evidence
that absorption of TB drugs in adults with HIV/AIDS is
worse compared with non-HIV-infected patients (Peloquin
et al. 1996). Although HIV infection is a risk factor for
ATDH, this could explain why ATDH is seen less
frequently in our HIV-infected population. Possibly,
immunosuppresion in patients with advanced AIDS results
in fewer side effects during TB treatment. Fourth, ethnic
variation causes differences in susceptibility for drug
toxicity. Phenotypic variation in human drug metabolism
can be attributed to polymorphisms in genes encoding
drug-metabolising enzymes. Such polymorphisms may
alter enzyme activity and could subsequently increase
formation of reactive metabolites(Wilkinson 2005). In the
case of isoniazid, toxic metabolites are responsible for its
toxicity. Possibly, genetic polymorphisms in drug metabo-
lising enzymes explain the low incidence of ATDH in sub-
Saharan populations. On the other hand, in our trial all
patients were HIV-positive and were on CTX prophylaxis
during TB treatment. Because HIV is a risk factor for
ATDH, a higher rate of ATDH would have been expected
(Yee et al. 2003). Cotrimoxazole can be hepatotoxic,
especially in patients with AIDS (Kovacs et al. 1984).
Therefore, the real incidence of ATDH in patients without
concomitant CTX may even be lower.
These ﬁndings are an incentive to study ATDH in sub-
Saharan Africa. Because of the HIV epidemic, TB rates are
increasing in this region. Furthermore, HIV not only
increases the burden of tuberculosis in Africa, but also
complicates its therapy. Drug interactions and overlapping
toxicities are often seen during combined HIV/TB treat-
ment, and drug toxicity has been implicated as a major
cause of treatment interruption (Dean et al. 2002; Kwara
et al. 2005). Currently antiretroviral drugs are being
introduced on a large scale in sub-Saharan Africa. Our
ﬁndings are encouraging in that hepatotoxicity due to
combined HIV/TB treatment may occur less frequently
than expected. However, more studies are needed on
hepatotoxicity of combined treatment, in particular, in
relation to the degree of immunosuppression as TB can
occur at any CD4 level. In addition, more research on the
incidence and risk factors for ATDH in Africans may help
to prevent serious hepatotoxicity during TB and combined
HIV/TB treatment. The prevention of side effects increases
treatment adherence and treatment success rates. This will
eventually contribute to better TB and HIV control.
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La fre ´quence d’he ´patotoxicite ´ induite par les antituberculeux est inopine ´ment faible chez les patients a ` tuberculose pulmonaire, infecte ´s par le VIH
au Malawi
La proportion de patients avec une he ´patotoxicite ´ induite par les antituberculeux e ´tait inopine ´ment faible au cours d’une e ´tude sur la prophylaxie au
cotrimoxazole chez les patients malawiens a ` tuberculose (TB) pulmonaire et VIH positifs. Environ 2% des patients ont de ´veloppe ´ une he ´patotoxicite ´ de
grade 2 ou 3, selon les de ´ﬁnitions de l’OMS, durant le traitement de la tuberculose. Les donne ´es sur l’he ´patotoxicite ´ induite par les antituberculeux en
Afrique subsaharienne sont limite ´es. Bien que les nombres de cas ne soient pas tre `se ´leve ´s, notre e ´tude ainsi que d’autres sugge `rent que l’he ´patotoxicite ´
induite par les antituberculeux n’est pas courante dans cette re ´gion. Ces re ´sultats sont encourageants, l’he ´patotoxicite ´ e ´tant peut e ˆtre un proble `me moins
important que pre ´vu, particulie `rement a ` la lueur du traitement combine ´ VIH/TB, ou ` la toxicite ´ des me ´dicaments est une cause importante d’interruption
du traitement.
mots cle ´s Effets adverses, affection he ´patique induite par les medicaments, traitement de la tuberculose, Mycobactium tuberculosis, VIH
La hepatotoxicidad inducida por fa ´rmacos antituberculosos es inesperadamente baja en pacientes VIH positivos con tuberculosis pulmonar,
en Malawi
La proporcio ´n de pacientes con hepatotoxicidad inducida por fa ´rmacos antituberculosos (HFAT) fue inesperadamente baja durante un ensayo con
cotrimoxazol como proﬁlaxis, en pacientes VIH positivos con tuberculosis pulmonar, en Malawi. Alrededor de un 2% los pacientes desarrollaron un
hepatotoxicidad grado 2 o 3 durante el tratamiento para la TB, de acuerdo con las deﬁniciones de la OMS. Los datos sobre HFAT en A ´ frica
Subsahariana son limitados. Aunque los nu ´meros no son muy so ´lidos, nuestro ensayo clı ´nico y otro artı ´culo publicado sugieren que la HFAT no es
comu ´n en esta regio ´n. Estos hallazgos son alentadores en el sentido de que la hepatotoxicidad puede ser un problema menor de lo esperado,
especialmente en un tratamiento suave combinado VIH/TB, en el que la toxicidad por fa ´rmacos es la mayor causa de interrupcio ´n del tratamiento.
palabras clave Efectos adversos, enfermedad hepa ´tica inducida por fa ´rmacos, tratamiento tuberculosis, Mycobacterium tuberculosis, VIH
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